Research programme: nanotechnology-based therapeutics - Qualiber

Drug Profile

Research programme: nanotechnology-based therapeutics - Qualiber

Alternative Names: Nano GTP; Nano VP16; NanoSi CD36

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Qualiber
  • Class Deoxyribonucleosides; Pyrimidine nucleosides; Small interfering RNA; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Hepatitis B; Lung cancer; Lymphoma; Pancreatic cancer

Most Recent Events

  • 27 Sep 2016 Early research in Hepatitis B in USA (unspecified route) before September 2016
  • 27 Sep 2016 Early research in Lung cancer in USA (unspecified route) before September 2016
  • 27 Sep 2016 Early research in Lymphoma in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top